Interim 18F-FDG positron emission tomography/computed tomography during chemoradiotherapy in the management of cancer patients: a response [Letter] by Hargreaves, S. et al.
Interim 18F-FDG Positron Emission Tomography/Computed Tomography during 
chemoradiotherapy in the management of cancer patients: A response 
 
As outlined by Garibaldi et al in their recent letter (1), there is increasing interest in the use of Positron 
Emission Tomography – Computed Tomography (PET-CT) to demarcate the Biological Gross Tumour 
Volume (bGTV) for radical radiotherapy treatment. In head and neck cancers, 18F-Fluorodeoxyglucose 
(18F-FDG)-PET-CT defined volumes have been shown to correlate with pathological specimens better 
than other imaging modalities (2). Additionally, PET-CT carried out at baseline (3) and/or during 
treatment (4), may offer prognostic and/or predictive information (5, 6).  
Adaptive radiotherapy (ART) - the alteration of a treatment plan based upon anatomical changes 
during radiotherapy - is a rapidly growing area. ART could improve normal tissue sparing (7) or, 
conversely, escalate radiotherapy doses to poorly responding tumours (8). 
Garibaldi’s critical review of the utility of interim PET-CT (iPET) in head and neck cancer treatment (9) 
concluded there was a need for further research into its predictive and/or prognostic role. They called 
for more homogenous cohorts of patients and treatment regimens, and a standardised method of 
analysing PET data.  
The PEARL study (NCT number pending) is a multicentre phase II feasibility study designed to explore 
the potential of 18-FDG-PET-CT-based ART to reduce toxicity in radically treated patients with low risk 
(10) Human Papilloma Virus positive oropharyngeal squamous cell carcinoma.  Patients will undergo 
iPET after 2 weeks  of conventionally fractionated IMRT.  
ATLAAS (Automatic decision-Tree Learning Algorithm for Advanced Segmentation of PET images), a 
machine learning tool, will define the bGTV on the baseline and interim PET-CT (11). We have shown 
that ATLAAS can be trained to outperform any other individual PET-based automated segmentation 
algorithm (12) and is a useful tool in the standardisation of PET-based segmentation within clinical 
radiotherapy trials.  
PEARL will address many of the shortcomings identified by Garibaldi et al. Furthermore, PEARL will 
offer important insight into the feasibility of PET-based ART to improve outcomes.  
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